ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2824

Antibiotic Use and the Development of Rheumatoid Arthritis (RA) and Risk of RA Flares: Case-Control and Self-Controlled Case Series Studies in Two National Electronic Patient Databases (SIDIAP and CPRD)

Navraj Nagra1, Danielle Robinson 2, Antonella Delmestri 1, Stephanie Dakin 1, Sarah Snelling 1, Andrew Carr 1 and Daniel Prieto-Alhambra 1, 1University of Oxford, Oxford, United Kingdom, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: antibiotics and Electronic Health Record, Epidemiologic methods, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T109: Epidemiology & Public Health III: RA (2822–2827)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: The microbiome and specific bacterial triggers have been hypothesised to be involved in the pathogenesis of Rheumatoid Arthritis (RA) and RA flares. Antibiotic usage can mediate changes in the microbiome, and act as a surrogate for infection with potentially pathogenic bacteria. We aimed to determine the association of antibiotic usage and RA/RA flare diagnosis.

Methods: Analyses were performed using the Catalan SIDIAP, and UK CPRD, national electronic primary care databases. Within SIDIAP, patients with an initial diagnosis of RA and 5 age, gender and practice matched patients were selected. Missing data (present for BMI, smoking and alcohol drinking) was imputed using multiple imputation with chained equations. Within CPRD, RA diagnosed patients with ≥1 RA flare recorded were included.

We performed a case-control study using SIDIAP and a self-controlled case series (SCCS) study using the UK CPRD. 

Antibiotics grouped by the WHO ATC classification were the study exposures. Outcomes of interest were initial RA diagnosis in SIDIAP and RA flare in CPRD. 

Multivariate conditional logistic regression was performed using SIDIAP data to determine associations with specific antibiotic group use, controlling for age, BMI, gender, smoking status, alcohol consumption socioeconomic status, medical co-morbidities, primary care attendance and other antibiotic group use. Conditional fixed-effects Poisson regression models were used to determine incidence rate ratios of RA flares in relation to antibiotic usage within CPRD.

Results: 13,920 RA patients and 69,535 controls from the SIDIAP database were identified. Use of beta-lactams or quinolones in the 2 years prior to diagnosis were associated with RA (OR 1.23, 1.16-1.29; OR 1.32, 1.26-1.38 respectively; p< 0.0001). Only beta-lactams showed a consistent dose-response gradient (Q1 OR 1.19, 1.10-1.29; Q2 OR 1.22, 1.12-1.34; Q3 OR 1.31, 1.20-1.42; Q4 OR 1.42, 1.31-1.54; p< 0.0001) and association with recency of use (current: OR 1.82, 1.61-2.06; recent: OR 1.54, 1.36-1.74; and previous use: OR 1.20, 1.14-1.26, p< 0.0001). In parallel, 1,192 RA patients were identified from the CPRD (from 31,992 patients), with ≥1 flare/s recorded. Sulphonamide and trimethoprim use was associated with an increased risk of RA flare at 29-90 days (IRR 1.71, CI 1.12–2.59, p=0.012); 91-183 days (IRR 1.57, CI 1.06–2.33, p=0.025); and 184-365 days (IRR 1.44, CI 1.03–2.02, p=0.033) after antibiotic treatment commencement. No other antibiotic groups were associated with RA or RA flare risk.

Conclusion: Usage of broad-spectrum beta-lactam antibiotics was associated with index RA diagnosis in the Catalan population in a dose and time-dependent manner. Usage of sulphonamide and trimethoprim antibiotics appeared associated with a 70% increased risk of RA flare at 1-3 months, which remained significant up to 12 months after treatment. We hypothesise that antibiotic use is a surrogate of a pathogenic bacterial infection in index RA and that the delayed onset of RA flares after specific antibiotics is mediated through the gut or urinary microbiomes. Further epidemiological and mechanistic research is also needed to determine whether acute infections are associated with RA.


Disclosure: N. Nagra, None; D. Robinson, None; A. Delmestri, None; S. Dakin, None; S. Snelling, None; A. Carr, None; D. Prieto-Alhambra, None.

To cite this abstract in AMA style:

Nagra N, Robinson D, Delmestri A, Dakin S, Snelling S, Carr A, Prieto-Alhambra D. Antibiotic Use and the Development of Rheumatoid Arthritis (RA) and Risk of RA Flares: Case-Control and Self-Controlled Case Series Studies in Two National Electronic Patient Databases (SIDIAP and CPRD) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/antibiotic-use-and-the-development-of-rheumatoid-arthritis-ra-and-risk-of-ra-flares-case-control-and-self-controlled-case-series-studies-in-two-national-electronic-patient-databases-sidiap-and-cpr/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibiotic-use-and-the-development-of-rheumatoid-arthritis-ra-and-risk-of-ra-flares-case-control-and-self-controlled-case-series-studies-in-two-national-electronic-patient-databases-sidiap-and-cpr/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology